Effect of renal function on pemetrexed-induced haematotoxicity

Cancer, chemotherapy, and pharmacology [Epub ahead of print] [ Link] Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Abstract PURPOSE: Pemetrexed (PEM) is an anticancer agent used for the treatment of non-small cell lung cancer, malignant pleural…

Read More

Use of Quality Metrics for a New Hypo-Fractionated Pre-Surgical Mesothelioma Protocol

Medical Physics 2015 June [Link] Richardson S, Mehta V. Abstract Purpose The “SMART” (Surgery for Mesothelioma After Radiation Therapy) approach involves hypo-fractionated radiotherapy of the lung pleura to 25Gy over 5 days followed by surgical resection within 7. Early clinical results suggest that this approach is very promising, but also logistically challenging due to the…

Read More

Targeted therapies in malignant pleural mesothelioma: a review of clinical studies

Anticancer Drugs. 2011 Mar;22(3):199-205. [Link] Greillier L, Marco S, Barlesi F. Service d’Oncologie Multidisciplinaire et Innovations Thérapeutiques, Université de la Méditerranée-Assistance Publique Hôpitaux de Marseille, Marseille, France. Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose exposure to asbestos fibers is the main etiology. The incidence of MPM is anticipated to…

Read More

Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma

Neoplasia. 2011 Jan;13(1):12-22. [Link] Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA. Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA. Abstract The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR) and MET are activated in subsets of mesothelioma, suggesting that these kinases might represent novel therapeutic…

Read More

Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer

Journal of Thoracic Oncology. 2011 Jan 4. [Epub ahead of print] [Link] KaoSubramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R. *Division of Oncology, Department of Medicine, Washington University School of Medicine; †Department of Medicine, Alvin J Siteman Cancer Center at Washington University School of Medicine, St Louis, Missouri; and ‡Department of Medicine, Centre…

Read More

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma

Annals of Surgical Oncology. 2009 Jan;16(1):152-8. Epub 2008 Nov 8. [Link] Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Division of Surgical Oncology, Creighton University Medical Center, Creighton University, Omaha, NE 68131, USA. jasonfoster@creighton.edu Abstract Malignant peritoneal mesotheliomas (MPM) are rare tumors representing 20% of all malignant mesothelioma cases. The median survival for…

Read More

Systemic Treatments for Mesothelioma: Standard and Novel

Current Treatment Options in Oncology. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3. [Link] Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery. For…

Read More

The serine protease HtrA1 is a novel prognostic factor for human mesothelioma

Pharmacogenomics. 2008 Aug;9(8):1069-77. [Link] Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, Citro G, Ceribelli A, Mirri A, Chien J, Shridhar V, Ehrmann M, Santini M, Facciolo F. Department of Biochemistry and Biophysics, Section of Pathology, Second University of Naples, Via…

Read More

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma

Journal of Cancer Research and Clinical Oncology. 2008 Apr 8 [Epub ahead of print] [Link] Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Science, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. Abstract Epidermal growth factor receptor…

Read More